Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people on Medicare and those who can no longer access compounded tirzepatide.

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

In Wednesday's "Need to Know" column, Barbara Kollmeyer shared words of wisdom from Larry Swedroe, who has written many books about investing during a long career managing money. He quoted Buffett and ...

The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...

DIsney says it has sold out all commercial inventory for Sunday's Oscars, and notes packages include TV, streaming, social ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report). The company’s shares closed ...

Eli Lilly is making a massive $50 billion investment in U.S. manufacturing. This move more than doubles their previous $23 ...